{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02115295",
            "orgStudyIdInfo": {
                "id": "2012-0648"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2014-01103",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "2012-0648",
                    "type": "OTHER",
                    "domain": "M D Anderson Cancer Center"
                }
            ],
            "organization": {
                "fullName": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia",
            "officialTitle": "Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML",
            "therapeuticArea": [
                "Rare Diseases",
                "Oncology and Hematology",
                "Other",
                "Orthopedics"
            ],
            "study": "cladribine-idarubicin-cytarabine-and-venetoclax-in-treating-patients-with-acute-myeloid-leukemia-high-risk-myelodysplastic-syndrome-or-blastic-phase-chronic-myeloid-leukemia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2014-05-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2014-04-14",
            "studyFirstSubmitQcDate": "2014-04-14",
            "studyFirstPostDateStruct": {
                "date": "2014-04-16",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-04-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.",
            "detailedDescription": "Primary Objectives:\n\nI. To determine the complete response rate (CR) of cladribine in combination with idarubicin and cytarabine (araC) in patients with acute myeloid leukemia (AML), high risk (HR) myelodysplastic syndrome (MDS), or myeloid blast phase of chronic myeloid leukemia (CML).\n\nSecondary Objectives:\n\nI. To determine the overall response rate (ORR) of cladribine in combination with idarubicin and araC in patients with AML, HR MDS, or myeloid blast phase of CML.\n\nII. To assess overall survival (OS) and event free survival (EFS) of patients treated with cladribine, idarubicin, and araC (cytarabine).\n\nIII. To assess the duration of response to the combination in patients with AML, HR MDS, or myeloid blast phase of CML.\n\nIV. To determine the safety and tolerability of the combination in patients with AML, HR MDS, or myeloid blast phase of CML.\n\nExploratory Objectives:\n\nI. To study and describe the relationship between pretreatment patient/disease characteristics (including AML-associated molecular abnormalities) and outcome.\n\nII. To identify molecular biomarkers predictive of response to therapy.\n\nIII. To study and describe the relationship between patient/disease characteristics, use of intrathecal prophylaxis, and incidence of leptomeningeal disease.\n\nIV. To study the trajectories of leukemia mutations and molecular minimal residual disease (MRD) during the therapy.\n\nOUTLINE:\n\nINDUCTION: Patients receive cladribine intravenously (IV) and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax orally (PO) on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO twice daily (BID) on days 6-19 or gilteritinib PO once daily (QD) on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study treatment, patients are followed up every 6-12 months."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Biphenotypic Leukemia",
                "Acute Myeloid Leukemia",
                "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
                "Blasts 10 Percent or More of Bone Marrow Nucleated Cells",
                "Blasts 10 Percent or More of Peripheral Blood White Cells",
                "de Novo Myelodysplastic Syndrome",
                "Myelodysplastic Syndrome",
                "Previously Treated Myelodysplastic Syndrome",
                "Recurrent Acute Myeloid Leukemia",
                "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
                "Refractory Acute Myeloid Leukemia",
                "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
                "Secondary Acute Myeloid Leukemia",
                "Untreated Adult Acute Myeloid Leukemia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 508,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment (cladribine, cytarabine, idarubicin)",
                    "type": "EXPERIMENTAL",
                    "description": "INDUCTION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.",
                    "interventionNames": [
                        "Drug: Cladribine",
                        "Drug: Cytarabine",
                        "Drug: Gilteritinib",
                        "Drug: Idarubicin",
                        "Other: Laboratory Biomarker Analysis",
                        "Drug: Midostaurin",
                        "Drug: Venetoclax"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cladribine",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Treatment (cladribine, cytarabine, idarubicin)"
                    ],
                    "otherNames": [
                        "2-CdA",
                        "2CDA",
                        "CdA",
                        "Cladribina",
                        "Leustat",
                        "Leustatin",
                        "Leustatine",
                        "RWJ-26251"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cytarabine",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Treatment (cladribine, cytarabine, idarubicin)"
                    ],
                    "otherNames": [
                        ".beta.-Cytosine arabinoside",
                        "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone",
                        "1-.beta.-D-Arabinofuranosylcytosine",
                        "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone",
                        "1-Beta-D-arabinofuranosylcytosine",
                        "1.beta.-D-Arabinofuranosylcytosine",
                        "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-",
                        "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-",
                        "Alexan",
                        "Ara-C",
                        "ARA-cell",
                        "Arabine",
                        "Arabinofuranosylcytosine",
                        "Arabinosylcytosine",
                        "Aracytidine",
                        "Aracytin",
                        "Aracytine",
                        "Beta-cytosine Arabinoside",
                        "CHX-3311",
                        "Cytarabinum",
                        "Cytarbel",
                        "Cytosar",
                        "Cytosine Arabinoside",
                        "Cytosine-.beta.-arabinoside",
                        "Cytosine-beta-arabinoside",
                        "Erpalfa",
                        "Starasid",
                        "Tarabine PFS",
                        "U 19920",
                        "U-19920",
                        "Udicil",
                        "WR-28453"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Gilteritinib",
                    "description": "Given PO",
                    "armGroupLabels": [
                        "Treatment (cladribine, cytarabine, idarubicin)"
                    ],
                    "otherNames": [
                        "ASP-2215",
                        "ASP2215",
                        "Xospata"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Idarubicin",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Treatment (cladribine, cytarabine, idarubicin)"
                    ],
                    "otherNames": [
                        "4-Demethoxydaunomycin",
                        "4-demethoxydaunorubicin",
                        "4-DMDR"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Laboratory Biomarker Analysis",
                    "description": "Correlative studies",
                    "armGroupLabels": [
                        "Treatment (cladribine, cytarabine, idarubicin)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Midostaurin",
                    "description": "Given PO",
                    "armGroupLabels": [
                        "Treatment (cladribine, cytarabine, idarubicin)"
                    ],
                    "otherNames": [
                        "CGP 41251",
                        "CGP41251",
                        "N-Benzoyl-Staurosporine",
                        "N-Benzoylstaurosporine",
                        "PKC-412",
                        "PKC412",
                        "Rydapt"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Venetoclax",
                    "description": "Given PO",
                    "armGroupLabels": [
                        "Treatment (cladribine, cytarabine, idarubicin)"
                    ],
                    "otherNames": [
                        "ABT-0199",
                        "ABT-199",
                        "ABT199",
                        "GDC-0199",
                        "RG7601",
                        "Venclexta",
                        "Venclyxto"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Complete response (CR) rate",
                    "description": "CR rate will be determined.",
                    "timeFrame": "Up to 12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall response rate (ORR)",
                    "description": "ORR will be determined.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "OS will be assessed.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Event-free survival (EFS)",
                    "description": "EFS will be assessed.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Duration of response",
                    "description": "Duration of response will be assessed.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Incidence of toxicities",
                    "description": "Safety and tolerability of cladribine in combination with idarubicin and cytarabine will be determined.",
                    "timeFrame": "Up to 12 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Use of intrathecal prophylaxis",
                    "description": "The relationship between patient/disease characteristics and use of intrathecal prophylaxis will be studied and described.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Incidence of leptomeningeal disease",
                    "description": "The relationship between patient/disease characteristics and incidence of leptomeningeal disease will be studied and described.",
                    "timeFrame": "Up to 12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with a diagnosis of AML, Acute Biphenotypic Leukemia, or high risk MDS (\\>/= 10% blasts or IPSS \\>/= intermediate-2) will be eligible. Patients with CML in Myeloid Blast Phase are also eligible.\n2. For Frontline cohort (1 or 4): No prior potentially-curative therapy for leukemia. Prior therapy with hydroxyurea, hematopoietic growth factors, azacytidine, decitabine, ATRA, or a total dose of cytarabine up to 2g (for emergency use for stabilization) is allowed. Patients deemed able to receive venetoclax (ie. insurance clearance) will be assigned to Frontline cohort 4. Patients with secondary AMLwho have been treated for their antecedent myeloid neoplasm will be enrolled into the separate Secondary AML cohort.\n3. For Salvage cohort: Patients with previously treated, relapsed or refractory AML, Acute Biphenotypic Leukemia, or CML in Myeloid Blast Phase are eligible.\n4. Age \\</= 65 years.\n5. Adequate organ function as defined below:\n\n   * liver function (bilirubin \\< 2mg/dL, AST and/or ALT \\<3 x ULN - or \\<5 x ULN if related to leukemic involvement)\n   * kidney function (creatinine \\< 1.5 x ULN ).\n   * known cardiac ejection fraction of \\> or = 45% within the past 6 months\n6. ECOG performance status of \u2264 2.\n7. A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.\n8. Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient is required prior to their enrollment on the protocol.\n\nExclusion Criteria:\n\n1. Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided.\n2. Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n3. Patient with documented hypersensitivity to any of the components of the chemotherapy program.\n4. Men and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Tapan Kadia",
                    "role": "CONTACT",
                    "phone": "713-792-7305",
                    "email": "tkadia@mdanderson.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Tapan M Kadia",
                    "affiliation": "M.D. Anderson Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "M D Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tapan M. Kadia",
                            "role": "CONTACT",
                            "phone": "713-792-7305"
                        },
                        {
                            "name": "Tapan M. Kadia",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "34329576",
                    "type": "DERIVED",
                    "citation": "Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7."
                },
                {
                    "pmid": "29702001",
                    "type": "DERIVED",
                    "citation": "Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 Jun 20;36(18):1788-1797. doi: 10.1200/JCO.2017.77.6757. Epub 2018 Apr 27."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "University of Texas MD Anderson Cancer Center Website",
                    "url": "http://www.mdanderson.org"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015470",
                    "term": "Leukemia, Myeloid, Acute"
                },
                {
                    "id": "D000011289",
                    "term": "Preleukemia"
                },
                {
                    "id": "D000015464",
                    "term": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
                },
                {
                    "id": "D000001752",
                    "term": "Blast Crisis"
                },
                {
                    "id": "D000015456",
                    "term": "Leukemia, Biphenotypic, Acute"
                },
                {
                    "id": "D000009190",
                    "term": "Myelodysplastic Syndromes"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                },
                {
                    "id": "D000012008",
                    "term": "Recurrence"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000011230",
                    "term": "Precancerous Conditions"
                },
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000002471",
                    "term": "Cell Transformation, Neoplastic"
                },
                {
                    "id": "D000063646",
                    "term": "Carcinogenesis"
                },
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000007945",
                    "term": "Leukemia, Lymphoid"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "asFound": "Recurrent",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18123",
                    "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
                    "asFound": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14164",
                    "name": "Preleukemia",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12145",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18118",
                    "name": "Leukemia, Biphenotypic, Acute",
                    "asFound": "Acute Biphenotypic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5033",
                    "name": "Blast Crisis",
                    "asFound": "Blast Phase",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14111",
                    "name": "Precancerous Conditions",
                    "relevance": "LOW"
                },
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M5720",
                    "name": "Cell Transformation, Neoplastic",
                    "relevance": "LOW"
                },
                {
                    "id": "M30145",
                    "name": "Carcinogenesis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                },
                {
                    "id": "M10951",
                    "name": "Leukemia, Lymphoid",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "asFound": "Chronic",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1309",
                    "name": "Chronic Myeloid Leukemia",
                    "asFound": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3993",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "T174",
                    "name": "Acute Leukemia of Ambiguous Lineage",
                    "asFound": "Acute Biphenotypic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003561",
                    "term": "Cytarabine"
                },
                {
                    "id": "C000055994",
                    "term": "2-chloro-3'-deoxyadenosine"
                },
                {
                    "id": "C000579720",
                    "term": "Venetoclax"
                },
                {
                    "id": "D000015255",
                    "term": "Idarubicin"
                },
                {
                    "id": "D000017338",
                    "term": "Cladribine"
                },
                {
                    "id": "C000059539",
                    "term": "Midostaurin"
                },
                {
                    "id": "C000609080",
                    "term": "Gilteritinib"
                },
                {
                    "id": "D000019311",
                    "term": "Staurosporine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000092004",
                    "term": "Tyrosine Kinase Inhibitors"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M249656",
                    "name": "Venetoclax",
                    "asFound": "EEG",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6766",
                    "name": "Cytarabine",
                    "asFound": "Defined",
                    "relevance": "HIGH"
                },
                {
                    "id": "M257802",
                    "name": "2-chloro-3'-deoxyadenosine",
                    "asFound": "Intracerebral Hemorrhage",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19625",
                    "name": "Cladribine",
                    "asFound": "Platinum-based",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17958",
                    "name": "Idarubicin",
                    "asFound": "VEGF",
                    "relevance": "HIGH"
                },
                {
                    "id": "M58265",
                    "name": "Gilteritinib",
                    "asFound": "Firstly",
                    "relevance": "HIGH"
                },
                {
                    "id": "M353083",
                    "name": "Midostaurin",
                    "asFound": "Relearning",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21292",
                    "name": "Staurosporine",
                    "asFound": "Rheumatic Heart Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M344727",
                    "name": "2'-deoxyadenosine",
                    "relevance": "LOW"
                },
                {
                    "id": "M340203",
                    "name": "Cordycepin",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M2889",
                    "name": "Tyrosine Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}